Highlights
-
•
Multiple neuro-ophthalmological manifestations have been described in association with COVID-19.
-
•
These include optic neuritis, cranial nerve palsies, eye movement abnormalities and visual field defects.
-
•
A post-viral inflammatory syndrome, sequelae of a proinflammatory state, hypoxia and severe hypertension are often responsible.
Keywords: COVID-19 infection, Neuro-ophthalmology, Optic neuritis, Cranial nerve palsy, Miller-Fisher variant Guillain Barre syndrome, Myasthenia gravis, Opsoclonus, Diplopia, Oscillopsia, Visual field defect, Stroke, Venous sinus thrombosis
Abstract
Multiple neuro-ophthalmological manifestations have been described in association with COVID-19. These symptoms and signs may be the result of a range of pathophysiological mechanisms throughout the course from acute illness to recovery phase. Optic nerve dysfunction, eye movement abnormalities and visual field defects have been described.
1. Introduction
In December 2019 reports of severe acute respiratory syndrome (SARS-CoV-2) due to coronavirus disease 2019 (COVID-19) causing pneumonia emerged out of Wuhan city in China [1]. The enveloped RNA betacoronavirus is hypothesized to employ the ACE2 binding receptor for infectivity [1,2]. At the time of this article, it was confirmed to have infected nearly 34.5 million people worldwide and caused over 1 million deaths, causing an immense impact on society at large [3].
While the most common symptoms include fever, cough, fatigue, and shortness of breath [1,4], COVID-19 is not purely a respiratory disease; indeed, the virus may produce a vast array of manifestations related to acute cardiac disease, acute kidney injury, vasculopathy, coagulopathy, elevated inflammatory markers, and neurological injury [5]. Presentations vary from completely asymptomatic carriers to severe illness with multiorgan failure and death [5]. Severe cases are typically characterized by a heightened inflammatory and coagulopathic response that is thought to play a prominent role in the pathogenesis and mortality that is associated with this virus [6].
2. Neuro-ophthalmic manifestations
Multiple neuro-ophthalmological manifestations have been described in association with COVID-19. These symptoms and signs may be the result of varying underlying pathophysiological mechanisms including hypoxia, severe hypertension, toxic metabolic processes, ischemic and hemorrhagic strokes along with para-infectious and post-infectious inflammatory processes.
2.1. Optic neuritis
Cases of optic neuritis have been described in patients who had proven COVID-19 infection. In a study examining the neurological complications of COVID-19 admitted to a single hospital in Spain, one case of optic neuritis was observed in the recovery phase [4]. Additionally there have been case reports of MOG antibody positivity in patients with either presumed [7] or confirmed [8] COVID-19 infection. One had bilateral optic nerve abnormalities including peripheral retinal hemorrhages that responded well to intravenous corticosteroids [8]. Presumably the COVID-19 infection triggered an autoimmune response and the production of MOG antibodies. It is unclear whether the patient harbored a predisposition to MOG associated disease or if the virus set the process in motion. An additional case of optic neuritis that was associated with other neurological deficits and consistent with acute disseminated encephalomyelitis (ADEM) has also been documented [9].
2.2. Cranial nerve palsies
Both diplopia and ptosis have been described in patients shortly after diagnosis with typical COVID-19 infection. Several patients with ocular motor deficits within days of resolution of typical COVID-19 symptoms have been reported. These ocular motility deficits have been associated with paresthesias and hyporeflexia, suggesting the Miller-Fisher variant of the Guillain Barre syndrome [[10], [11], [12], [13], [14]]. In keeping with this diagnosis, cranial nerve inflammation on MRI has been observed [10].
In another case series, three patients presented with several days of fever and active COVID-19 infection. They did not have sensory complaints, but rather noted generalized fatigability. These patients were assessed with EMG, which showed decremental response on repetitive nerve stimulation and positive acetylcholine receptor antibodies, consistent with a diagnosis of Myasthenia Gravis. Again, the COVID-19 infection may have exposed an unrecognized predisposition to this autoimmune process. The patients in this series recovered with various immunosuppressive agents to treat Myasthenia Gravis [15]. An additional report of an isolated abducens nerve palsy without identifiable lesion on an imaging study and of unclear etiology was described during the height of the pandemic [16].
The hypercoagulable and proinflammatory state triggered by COVID-19 infection has been associated with cerebral venous sinus thromboses that may manifest with confusion and raised intracranial pressure. Increased intracranial pressure may produce a false localizing sixth nerve palsy as well as papilledema [[17], [18], [19]]. Pseudotumor cerebri syndrome has also been reported as a complication of multisystem inflammatory syndrome in children associated with COVID-19 infection [20]. Chemosis has also been described in patients with severe infection and significant ocular exudate [21].
2.3. Eye movement abnormalities and nystagmus
Oscillopsia has been described in several case reports in association with ataxia and myoclonus, usually in the context of encephalopathy and following severe systemic involvement due to COVID-19 infection. These patients were found to have corresponding cerebellar lesions on MRI and bland cerebrospinal fluid [22,23] consistent with a post-infectious immune-mediated rhomboencephalitis. In one case, the MRI did not show any structural lesion, however the time course of presentation, symptoms and bland CSF were felt to be consistent with this process [24]. A single case of opsoclonus myoclonus ataxia syndrome has been reported in a patient five days after resolution of fevers and myalgias typical of COVID-19 symptoms. There were no findings seen on brain MRI, but CT chest showed findings consistent with COVID-19 infection. The patient responded well to treatment with intravenous immunoglobulin and methylprednisolone treating an inflammatory cerebellar syndrome [25]. The authors (SLG personal communication) have also observed a patient with atypical ocular bobbing (slow phase up and fast phase down) in a patient who had transient white matter abnormalities in the bilateral superior cerebellar peduncles.
2.4. Visual field defects
Stroke, especially in the younger population, has been one of the most notable and devastating neurological complications of COVID-19. With involvement of the posterior circulation and occipital lobes, visual field defects and visual snow syndrome have been documented and reported in these patients [[26], [27], [28], [29], [30]]. The entity of posterior reversible vasoconstriction syndrome (PRES) has been another mechanism of injury in COVID-19 and some patients may experience transient visual field defects and MRI abnormalities [31]. There has been one report of hallucinatory palinopsia described in a patient with PRES due to COVID-19 infection with involvement of parieto-occipital lobes on MRI [32].
3. Conclusion
The neuro-ophthalmological symptoms and signs associated with COVID-19 infection are varied and span the course of infection through the recovery phase. The mechanisms of involvement are still in the process of being completely elucidated, however, they tend to fall within three general categories – a post-viral inflammatory syndrome, sequelae of a proinflammatory state with hypercoagulability and “cytokine storm,” and the result of systemic abnormalities including hypoxia and severe hypertension. Direct viral invasion seems to be a rare manifestation of COVID-19 and we are unaware of neuro-ophthalmological findings that have been definitively produced by this potential mechanism.
References
- 1.Guan W.J. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382(18):1708–1720. doi: 10.1056/NEJMoa2002032. Apr 30. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Lu R. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574. doi: 10.1016/S0140-6736(20)30251-8. Feb 22. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.WHO. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. (accessed).
- 4.Romero-Sánchez C.M. Neurologic manifestations in hospitalized patients with COVID-19. Neurology. 2020;95(8):e1060. doi: 10.1212/WNL.0000000000009937. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.High B., Hixon A.M., Tyler K.L., Piquet A.L., Pelak V.S. Neurology and the COVID-19 pandemic: gathering data for an informed response. Neurol. Clin. Pract. 2020 doi: 10.1212/CPJ.0000000000000908. p.10.1212/CPJ.0000000000000908. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Xie J., Tong Z., Guan X., Du B., Qiu H. Clinical characteristics of patients who died of coronavirus disease 2019 in China. JAMA Netw. Open. 2020;3(4):e205619. doi: 10.1001/jamanetworkopen.2020.5619. Apr 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.de Ruijter N.S., Kramer G., Gons R.A.R., Hengstman G.J.D. Neuromyelitis optica spectrum disorder after presumed coronavirus (COVID-19) infection: a case report. Mult. Scler. Relat. Disord. 2020;46:102474. doi: 10.1016/j.msard.2020.102474. 11/01/ 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Zhou S., Jones-Lopez E.C., Soneji D.J., Azevedo C.J., Patel V.R. Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis and myelitis in COVID-19. J. Neuroophthalmol. 2020;40(3):398–402. doi: 10.1097/WNO.0000000000001049. Sep. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Novi G. Acute disseminated encephalomyelitis after SARS-CoV-2 infection," (in eng) Neurol. Neuroimmunol. Neuroinflamm. 2020;7(5):e797. doi: 10.1212/NXI.0000000000000797. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Dinkin M. COVID-19 presenting with ophthalmoparesis from cranial nerve palsy. Neurology. 2020;95(5):221–223. doi: 10.1212/WNL.0000000000009700. Aug 4. [DOI] [PubMed] [Google Scholar]
- 11.Gutiérrez-Ortiz C. Miller Fisher syndrome and polyneuritis cranialis in COVID-19," (in eng) Neurology. 2020;95(5):e601–e605. doi: 10.1212/wnl.0000000000009619. Aug 4. [DOI] [PubMed] [Google Scholar]
- 12.Assini A., Benedetti L., Di Maio S. New clinical manifestation of COVID-19 related Guillain-Barre syndrome highly responsive to intravenous immunoglobulins: two Italian cases. Neurol Sci. 2020;41:1657–1658. doi: 10.1007/s10072-020-04484-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Reyes-Bueno J.A. Miller-Fisher syndrome after SARS-CoV-2 infection. Eur. J. Neurol. 2020;27(9):1759–1761. doi: 10.1111/ene.14383. 09/01 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Pinna P. Neurological manifestations and COVID-19: experiences from a tertiary care center at the frontline. J. Neurol. Sci. 2020;415:116969. doi: 10.1016/j.jns.2020.116969. 08/15/2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Restivo D.A., Centonze D., Alesina A., Marchese-Ragona R. Myasthenia Gravis Associated with SARS-CoV-2 Infection. Ann. Intern. Med. 2020;10(L20-845) doi: 10.7326/L20-0845. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Greer C., Bhatt J.M., Oliveira C.A., Dinkin M.J. Isolated Cranial Nerve 6 Palsy in 6 patients with COVID-19 infection. J. Neuroophthalmol. 2020;40(4):520–522. doi: 10.1097/WNO.0000000000001146. [DOI] [PubMed] [Google Scholar]
- 17.Shakibajahromi B., Borhani-Haghighi A., Haseli S., Mowla A. Cerebral venous sinus thrombosis might be under-diagnosed in the COVID-19 era," (in eng) eNeurologicalSci. 2020;20:100256. doi: 10.1016/j.ensci.2020.100256. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Cavalcanti D.D. Cerebral venous thrombosis associated with COVID-19," (in eng) AJNR Am. J. Neuroradiol. 2020;41(8):1370–1376. doi: 10.3174/ajnr.A6644. Aug. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Eliseeva N., Serova N., Yakovlev S., Mikeladze K., Arkhangelskaya Y., Gasparyan S. Neuro-ophthalmological features of cerebral venous sinus thrombosis," (in eng) Neuroophthalmology. 2014;39(2):69–76. doi: 10.3109/01658107.2014.953697. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Verkuil L.D., Liu G.T., Brahma V.L., Avery R.A. Pseudotumor cerebri syndrome associated with MIS-C: a case report. Lancet. 2020;396(10250):532. doi: 10.1016/S0140-6736(20)31725-6. 08/22/ 2020. [DOI] [PubMed] [Google Scholar]
- 21.Wu P. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol. 2020;138(5):575–578. doi: 10.1001/jamaophthalmol.2020.1291. May 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Llorente Ayuso L., Torres Rubio P., Beijinho do Rosário R.F., Giganto Arroyo M.L., Sierra-Hidalgo F. Bickerstaff encephalitis after COVID-19. J. Neurol. 2020 doi: 10.1007/s00415-020-10201-1. 09/03 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Wong P.F. Lessons of the month 1: a case of rhombencephalitis as a rare complication of acute COVID-19 infection. Clin. Med. 2020;20(3):293. doi: 10.7861/clinmed.2020-0182. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Khoo A. Postinfectious brainstem encephalitis associated with SARS-CoV-2. J. Neurol. Neurosurg. Psychiatr. 2020;91(9):1013. doi: 10.1136/jnnp-2020-323816. [DOI] [PubMed] [Google Scholar]
- 25.Sanguinetti S., Ramdhani R.A. Opsoclonus myoclonus Ataxia syndrome related to the novel coronavirus (COVID-19) J. Neuroophthalmol. 2020 doi: 10.1097/WNO.0000000000001129. Sep 7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Yaghi S. SARS-CoV-2 and stroke in a New York healthcare system. Stroke. 2020;51(7):2002–2011. doi: 10.1161/STROKEAHA.120.030335. 07/01 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Fifi J.T., Mocco J. COVID-19 related stroke in young individuals. Lancet Neurol. 2020;19(9):713–715. doi: 10.1016/S1474-4422(20)30272-6. 09/01/2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Mao L. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683–690. doi: 10.1001/jamaneurol.2020.1127. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Ellul M.A. Neurological associations of COVID-19. Lancet Neurol. 2020;19(9):767–783. doi: 10.1016/S1474-4422(20)30221-0. Sep. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Beyrouti R. Characteristics of ischaemic stroke associated with COVID-19. J Neurol. Neurosurg. Psychiatry. 2020;91(8):889–891. doi: 10.1136/jnnp-2020-323586. Aug. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Parauda S.C. Posterior reversible encephalopathy syndrome in patients with COVID-19. J. Neurol. Sci. 2020;416:117019. doi: 10.1016/j.jns.2020.117019. 09/15/ 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Ghosh R., Lahiri D., Dubey S., Ray B.K., Benito-Leon J. Hallucinatory Palinopsia in COVID-19-Induced Posterior Reversible Encephalopathy Syndrome. J. Neuroophthalmol. 2020;40(4):523–526. doi: 10.1097/WNO.0000000000001135. [DOI] [PubMed] [Google Scholar]